Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice
Open Access
- 27 June 2016
- journal article
- Published by Elsevier in Cancer Treatment Communications
- Vol. 6, S1-S10
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancerCancer Chemotherapy and Pharmacology, 2012
- An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II studyCancer Chemotherapy and Pharmacology, 2011
- Acceptance of oral chemotherapy in breast cancer patients - a survey studyBMC Cancer, 2011
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011
- International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent ChemotherapyJNCI: Journal of the National Cancer Institute, 2009
- All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II TrialBritish Journal of Cancer, 2009
- Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibitionMolecular Cancer Therapeutics, 2009
- Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancerCancer Chemotherapy and Pharmacology, 2009
- Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effectsAnnals of Oncology, 2005
- Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnnals of Oncology, 2002